

1644 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mukherjee et al.

Application No. 10/019,833 Filed: November 20, 2002 Confirmation No. 8664

For: UTEROGLOBIN IN THE TREATMENT

OF IGA MEDIATED AUTOIMMUNE

DISORDERS

Examiner: David A. Saunders, Ph.D.

Art Unit: 1644

Attorney Reference No. 4239-61375-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant

Date Mailed September 16, 2005

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

PATENT

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS.

However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Susan-Alpert Siegel, Ph.D Registration No. 43,121

One World Trade Center, Suite 1600

121 S.W. Salmon Street

Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

cc: Docketing

ONFORMATION DISCLOSURE STATEMENT BY APPLICANT

SEP 2 0 2005

Attorney Docket Number	4239-61375-01
Application Number	10/019,833
Filing Date	November 20, 2002
First Named Inventor	Mukherjee
Art Unit	1644
Examiner Name	David A. Saunders, Ph.D.

U.S. PATENT DOCUMENTS

Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,696,092	12-09-1997	Patierno et al.
	<u>.</u>			
<u></u>				
	l			

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

SAS:gsh	09/16/05	4239-61375-01	428729
0.10.50	02.10.00	1237 01313 01	120727

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-61375-01	
Application Number	10/019,833	
Filing Date	November 20, 2002	
First Named Inventor	Mukherjee	
Art Unit	1644	
Examiner Name	David A. Saunders, Ph.D.	

		Examiner Name David A. Sadilders, 1 i.D.		
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS		
		MANDAL, ASIM K., et al., "Uteroglobin Represses Allergen-induced Inflammatory Response by Blocking PGD ₂ Receptor-mediated Functions," <i>The Journal of Experimental Medicine</i> , May 17, 2004, pp. 1317-1330, Vol. 199, No. 10		
		KUNDU, GOPAL C., et al., "Uteroglobin (UG) Suppresses Extracellular Matrix Invasion by Normal and Cancer Cells that Express the High Affinity UG-binding Proteins," <i>The Journal of Biological Chemistry</i> , August 28, 1998, pp. 22819-22824, Vol. 273, No. 35		
		KUNDU, GOPAL C., et al., "Recombinant Human Uteroglobin Suppresses Cellular Invasiveness via a Novel Class of High-affinity Cell Surface Binding Site," <i>Proc. Natl. Acad. Sci. USA</i> , April 1996, pp. 2915-2919, Vol. 93		
(

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.